ANI Pharmaceuticals Q4 2024 Earnings Report
Key Takeaways
ANI Pharmaceuticals reported record Q4 2024 financial results, with a 44.8% increase in total net revenues to $190.6 million. The company's Rare Disease segment, including Cortrophin Gel, ILUVIEN, and YUTIQ, significantly contributed to this growth. Adjusted non-GAAP EBITDA increased by 65.7% to $50.0 million, and adjusted non-GAAP diluted earnings per share reached $1.63.
Total net revenues reached a record $190.6 million, a 44.8% year-over-year increase.
Rare Disease segment revenues totaled $87.0 million, including record Cortrophin Gel revenues of $59.4 million.
Adjusted non-GAAP EBITDA reached a record $50.0 million, a 65.7% year-over-year increase.
The company raised its 2025 guidance for net revenues to $756.0 million - $776.0 million and adjusted non-GAAP EBITDA to $190.0 million - $200.0 million.
ANI Pharmaceuticals
ANI Pharmaceuticals
Forward Guidance
ANI Pharmaceuticals raised its full year 2025 guidance, expecting increased net revenues and adjusted non-GAAP EBITDA.
Positive Outlook
- Net Revenue (Total Company) expected between $756 million - $776 million
- Cortrophin Gel Net Revenue expected between $265 million - $274 million
- ILUVIEN and YUTIQ Net Revenue expected between $97 million - $103 million
- Adjusted Non-GAAP EBITDA expected between $190 million - $200 million
- Adjusted Non-GAAP Diluted EPS expected between $6.12 - $6.49